Invitae Amends IPO Filing Targeting up to $92.3M; Signs Reimbursement Contract with SelectHealth | GenomeWeb

NEW YORK (GenomeWeb) – Invitae plans to offer 5,350,000 shares of its common stock at a price between $13 and $15 per share in its planned initial public offering, the firm said in an amended S-1 registration statement filed with the US Securities and Exchange Commission today.

Invitae had initially filed for an IPO last month, targeting $86 million in proceeds.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.